{
    "organizations": [],
    "uuid": "681f8ff866f636d61dd4f0bed1dabf7ca83608ab",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kalytera-announces-issuance-of-pat/brief-kalytera-announces-issuance-of-patent-covering-the-use-of-cbd-for-the-treatment-of-severe-and-refractory-graft-versus-host-disease-idUSFWN1RW0IK",
    "ord_in_thread": 0,
    "title": "BRIEF-Kalytera Announces Issuance Of Patent Covering The Use Of CBD For The Treatment Of Severe And Refractory Graft Versus Host Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Kalytera Therapeutics Inc:\n* KALYTERA ANNOUNCES ISSUANCE OF PATENT COVERING THE USE OF CBD FOR THE TREATMENT OF SEVERE AND REFRACTORY GRAFT VERSUS HOST DISEASE\n* KALYTERA THERAPEUTICS INC - KALYTERA ALSO EXPECTS TO INITIATE AN ADDITIONAL PHASE 2 CLINICAL STUDY IN TREATMENT OF GVHD LATER THIS YEAR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-19T19:38:00.000+03:00",
    "crawled": "2018-04-20T12:13:30.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "kalytera",
        "therapeutic",
        "inc",
        "kalytera",
        "announces",
        "issuance",
        "patent",
        "covering",
        "use",
        "cbd",
        "treatment",
        "severe",
        "refractory",
        "graft",
        "versus",
        "host",
        "disease",
        "kalytera",
        "therapeutic",
        "inc",
        "kalytera",
        "also",
        "expects",
        "initiate",
        "additional",
        "phase",
        "clinical",
        "study",
        "treatment",
        "gvhd",
        "later",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}